General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1O8 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects Bcl-xL. It targets an epitope within 13 amino acids from the N-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 13 amino acids from the N-terminal region of human Bcl-xL.
Application
Quality Control Testing
Evaluated by Western Blotting in COS-1 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Bcl-xL in COS-1 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Bcl-xL in MCF-7 and RAW264.7 cell lysates and 1:10,000 dilution detected the recombinant active form of Human Bcl-xL.
Flow Cytometry Analysis: 0.1 µg from a representative lot detected Bcl-xL in one million MCF-7 cells.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Bcl-xL in MCF-7 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Bcl-xL in human bone marrow tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Bcl-2-like protein 1 (UniProt: Q07817; also known as Bcl2-L-1, Apoptosis regulator Bcl-X, BCL-xL) is encoded by the BCL2L1 (also known as BCL2L, BCLX) gene (Gene ID: 598) in human. Bcl-xL is the most abundant Bcl-x protein that inhibits apoptosis by various mechanisms including the inhibition of Bax. It binds to Bax and prevents it from binding to the mitochondrial outer membrane. It can also induce the translocation of mitochondrial bound Bax to the cytoplasm, and can sequester tBid, which is an activator of Bax. Bcl-xL also regulates cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. It has four BH motifs. The BH4 motif is essential for its anti-apoptotic activity. The BH1 and BH2 motifs are required for both heterodimerization with other Bcl-2 family members and for repression of cell death. The loop between motifs BH4 and BH3 is required for the interaction with NLRP1. It is proteolytically cleaved by caspases during apoptosis and the cleaved protein that lacks the BH4 motif, has pro-apoptotic activity. Its caspase cleavage site is localized between amino acids 61-62. Bcl-xl undergoes phosphorylation on serine 62 by CDK1. This phosphorylation is partial in normal mitotic cells, but complete in G2-arrested cells upon DNA-damage, thus promoting subsequent apoptosis. Its phosphorylation at serine 49 occurs during the S and G2 phases and disappears rapidly in early mitosis. Overexpression of Bcl-xL has been linked with increased cell survival and higher expression is shown to promote the progression of breast and urothelial cancers and play a role in chemotherapy resistance. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Stevens, M., and Oltean, S. (2019). Front. Genet. 10; 804; Amundson, SA., et al. (2000). Cancer Res. 60(21); 6101-6110; Terrano, DT., et al. (2010). Mol. Cell Biol. 30(3); 640-656; Clem, RJ., et al. (1998). Proc. Natl. Acad. Sci. USA. 95(2); 554-559).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.